Non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease, is easily the world's largest untapped drug market. NASH drug sales, in fact, could exceed an eye-popping $62 billion as soon as 2028, according to various Wall Street analysts and industry insiders.
Which biotech companies are in the best position to benefit from this enormous commercial opportunity? Intercept Pharmaceuticals (NASDAQ: ICPT) and Viking Therapeutics (NASDAQ: VKTX) arguably sport two of the most promising experimental NASH therapies in their respective pipelines. As such, let's break down which of these NASH-oriented biotech stocks is the better buy right now.
Image Source: Getty Images.